BONUSCAP-ZERTIFIKAT - ELI LILLY & CO | Market Closed - Börse Stuttgart 19:28:20 23/05/2024 BST | ||
| 982.6 EUR | +0.89% |
|
| Current month | +17.04% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 23/05/24 | 982.6 | +0.89% |
| 22/05/24 | 973.9 | -1.65% |
| 21/05/24 | 990.3 | +7.11% |
| 20/05/24 | 924.6 | -0.43% |
| 17/05/24 | 928.6 | -4.79% |
Delayed Quote Börse Stuttgart
Last update May 23, 2024 at 07:28 pm
More quotesStatic data
| Product type | Bonus- and Part-Guarantee-Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD52AQ |
| ISIN | DE000HD52AQ1 |
| Date issued | 26/04/2024 |
| Strike | 1,350 $ |
| Maturity | 20/06/2025 (393 Days) |
| Parity | 1 : 1 |
| Emission price | 822.9 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1,001 € |
|---|---|
| Lowest since issue | 816.6 € |
| Spread | 0.3 € |
| Spread % | 0.03% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
808.4
USD
Average target price
850.8
USD
Spread / Average Target
+5.24%
- Stock Market
- Certificates
- Certificat
